和誉(02256.HK) 公布,其附属公司和誉医药的ABSK211新药临床试验(IND)申请,已获得国家药品监督管理局批准。ABSK211是一款口服、高效力小分子pan-KRAS抑制剂,对多种KRAS基因改变具有广谱活性,用于治疗携带KRAS基因改变的晚期实体瘤患者。此前,ABSK211已于7月8日获得美国食品药品监督管理局的IND批准。(sl/j)(港股报价延迟最少十五分钟。沽空资料截至 ...
Source Link和誉(02256.HK) 公布,其附属公司和誉医药的ABSK211新药临床试验(IND)申请,已获得国家药品监督管理局批准。ABSK211是一款口服、高效力小分子pan-KRAS抑制剂,对多种KRAS基因改变具有广谱活性,用于治疗携带KRAS基因改变的晚期实体瘤患者。此前,ABSK211已于7月8日获得美国食品药品监督管理局的IND批准。(sl/j)(港股报价延迟最少十五分钟。沽空资料截至 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.